Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Another Botox Competitor: Revance Prepares Longer-Lasting RT002 For BLA Submission

Feb 22 2019

• By Mandy Jackson

Clinic of Aesthetic Medicine. Botox / Disport Procedure for men.

Related Content

Mapping US FDA's Biosimilar Pathway With Pink Sheet Drug Review Profiles

Jul 26 2017

Mylan has biosimilar aspirations for Botox

Mar 09 2018

Revance's Long-Acting RT002 Will Have Slow-Moving Impact On Allergan

Dec 06 2017

Medical Aesthetics: Sales Rise For Popular Products, But Unmet Needs Remain

Sep 12 2018

With Jeuveau Approval, Evolus Will Focus On The Beauty Business To Gain Market Share

Feb 05 2019

Merz Neurology Business Boosted By Xeomin Sialorrhea OK

Jul 05 2018

Mylan Set To Develop Biosimilar Botox In Deal With Revance

Mar 01 2018

Asia Deal Watch: ReVance Licenses Chinese Rights To Botox Competitor To Fosun

Dec 05 2018

Related Companies

Revance Therapeutics, Inc.

Allergan plc

Viatris Inc.

Merz Pharmaceuticals GmbH

Ipsen SA

Evolus, Inc.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Additional Topics

Business Strategies Biosimilars Companies Commercial Aesthetics BioPharmaceutical

More from Strategy

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window